Journal article
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial
Abstract
AIMS: To analyse whether the benefits and risks of rivaroxaban plus aspirin vary in patients with comorbidities and receiving multiple drugs. In patients with coronary or peripheral artery disease, adding low-dose rivaroxaban to aspirin reduces cardiovascular events and mortality. Polypharmacy and multimorbidity are frequent in such patients.
METHODS AND RESULTS: We describe ischaemic events (cardiovascular death, stroke, or myocardial …
Authors
Vanassche T; Verhamme P; Anand SS; Shestakovska O; Leong DP; Fox KAA; Bhatt DL; Avezum A; Alings M; Aboyans V
Journal
European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 8, No. 5, pp. 462–473
Publisher
Oxford University Press (OUP)
Publication Date
August 11, 2022
DOI
10.1093/ehjcvp/pvab050
ISSN
2055-6837